Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $88 | $85 | $65 | $35 |
| % Growth | 3.4% | 30% | 87% | – |
| Cost of Goods Sold | $15 | $11 | $8 | $3 |
| Gross Profit | $72 | $73 | $58 | $32 |
| % Margin | 82.6% | 86.5% | 88.4% | 92.8% |
| R&D Expenses | $49 | $54 | $92 | $93 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $55 | $45 | $61 | $55 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $104 | $99 | $153 | $148 |
| Operating Income | -$31 | -$26 | -$95 | -$115 |
| % Margin | -35.6% | -30.3% | -145.3% | -330.8% |
| Other Income/Exp. Net | $1 | $5 | -$1 | $60 |
| Pre-Tax Income | -$30 | -$21 | -$96 | -$55 |
| Tax Expense | -$0 | $1 | $0 | $0 |
| Net Income | -$30 | -$21 | -$96 | -$55 |
| % Margin | -33.8% | -25.3% | -146.4% | -158.4% |
| EPS | -0.67 | -0.49 | -2.2 | -1.28 |
| % Growth | -36.7% | 77.7% | -71.9% | – |
| EPS Diluted | -0.67 | -0.49 | -2.2 | -1.28 |
| Weighted Avg Shares Out | 44 | 44 | 44 | 43 |
| Weighted Avg Shares Out Dil | 44 | 44 | 44 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $5 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$31 | -$25 | -$95 | -$54 |
| % Margin | -35% | -29.4% | -145.1% | -156.2% |